NCT04800627: Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MMR, MSI-H
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have tumors that express complete loss of MLH1, PMS2, MSH2 or MSH6 to be deemed mismatch repair deficient (dMMR); Patients must have demonstrated prior progression on or after anti-PD1/L1 based therapy
Exclusions: Patients with known, unstable, untreated, or symptomatic central nervous system (brain or leptomeningeal) metastases- see trial for details

Comments are closed.

Up ↑